Bristol-Myers Squibb Co. (BMS, NYSE: BMY) announced positive topline results from the planned interim analysis of the pivotal ACTION‑1 trial (NCT05477576), conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression‑free survival (PFS) for RYZ101 (²²⁵Ac‑DOTATATE) in patients with somatostatin receptor‑positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP‑NETs) who have progressed following Lutetium‑177 (Lu177)‑based therapy.
Regulatory & Trial Milestone
| Item | Detail |
|---|---|
| Sponsor | RayzeBio, Inc. – a Bristol Myers Squibb company |
| Trial | ACTION‑1 (NCT05477576), randomized Phase 3 |
| Product | RYZ101 (²²⁵Ac‑DOTATATE) – investigational targeted radiopharmaceutical |
| Population | SSTR+ GEP‑NETs progressing after Lu177‑based therapy |
| Analysis | Planned interim analysis |
| Primary Endpoint | PFS by blinded independent central review (BICR) – met, statistically significant and clinically meaningful |
| Safety | Consistent with the known RYZ101 safety profile |
| Next Steps | Full data presentation and regulatory discussions; timing Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: RYZ101, an investigational targeted radiopharmaceutical therapy comprised of DOTATATE bound to Actinium‑225 (²²⁵Ac).
- Targeting: The DOTATATE peptide binds somatostatin receptors overexpressed on GEP‑NET cells, delivering radiation selectively to tumor sites.
- Alpha‑Emitter Advantage: ²²⁵Ac is a highly potent alpha‑emitting radioisotope; alpha particles deposit high linear energy transfer over very short path lengths, enabling more lethal, localized tumor‑cell killing versus beta emitters such as Lu177, with limited damage to surrounding healthy tissue.
- Clinical Positioning: Designed for the post‑Lu177 refractory setting, where treatment options are scarce – a direct evolution of the radioligand therapy paradigm established by beta‑emitting agents.
Clinical Evidence – ACTION‑1 Phase 3 Trial
| Element | Detail |
|---|---|
| Design | Randomized, active‑controlled Phase 3 |
| Experimental Arm | RYZ101 (²²⁵Ac‑DOTATATE) |
| Control Arm | Investigator’s choice of standard of care – high‑dose or high‑frequency long‑acting somatostatin analogues, everolimus, or sunitinib |
| Primary Endpoint | PFS by BICR – statistically significant, clinically meaningful improvement achieved |
| Numeric PFS Results | Not disclosed (interim topline) |
| Safety | Consistent with the known RYZ101 safety profile; no new safety signals reported |
ACTION‑1 enrolled patients with SSTR+ GEP‑NETs who had progressed on prior Lu177‑based therapy, a population with high unmet need and limited evidence‑based options. The interim analysis was reviewed under a blinded independent central review framework, strengthening the robustness of the positive PFS readout.
Market Impact & Outlook
- Alpha‑Emitter Leadership: The positive Phase 3 readout positions RYZ101 as a potential first alpha‑emitting radioligand therapy to demonstrate pivotal‑trial success in the post‑Lu177 GEP‑NET setting, extending BMS’s franchise beyond beta‑emitter‑based paradigms.
- Addressing a Refractory Population: Patients progressing after Lu177‑DOTATATE currently fall back on somatostatin analogues, everolimus or sunitinib – options with modest efficacy. A significant PFS improvement over investigator’s choice standard of care would establish a new treatment benchmark.
- Radiopharmaceutical Category Momentum: The result reinforces the strategic rationale behind BMS’s acquisition of RayzeBio, amid intensifying big‑pharma competition for radioligand assets and manufacturing capacity.
- Regulatory Pathway: Topline Phase 3 success supports upcoming regulatory discussions in the U.S. and other markets; full data disclosure at a future medical congress is expected.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial results, regulatory submissions and commercial potential of RYZ101. Interim topline results are subject to further data verification, and actual outcomes may differ materially due to risks including final analysis results, regulatory review, and competitive dynamics in radiopharmaceutical therapy.-Fineline Info & Tech
